Supriya Lifescience Shares Jump as Recovery Gains Momentum

Spread love

Mumbai-based API maker continues its recovery from multi-month lows, backed by regulatory tailwinds, export momentum and a ₹1,000 crore revenue target

By S. JHA

Mumbai, April 27, 2026 — Shares of Supriya Lifescience Limited climbed over 8 percent on Monday, extending a recovery that has gathered pace through April as a series of positive catalysts — regulatory, operational and sectoral — realigned investor sentiment toward one of India’s specialist active pharmaceutical ingredient manufacturers.

The stock has been on a distinct upswing since early April. On April 1, Supriya Lifescience recorded a single-session gain of 7.35%, touching a day high of ₹622 and outperforming the BSE Pharmaceuticals and Biotechnology sector by 5.28 percentage points — a move that highlighted stock-specific momentum rather than a broad market tailwind. Monday’s 8 percent-plus advance builds on that trajectory, placing the stock well above where it traded through most of March.

The USFDA Trigger That Changed the Narrative

The clearest recent catalyst for Supriya’s revival has been a landmark regulatory clearance. Supriya Lifesciences rallied 4.10 percent to ₹645.90 after its manufacturing facility at Lote, Parshuram Industrial Area, Maharashtra received an Establishment Inspection Report from the US Food and Drug Administration. The USFDA had inspected the facility between February 2 and February 6, 2026, following which the regulator issued a Form 483 with one minor observation and classified the facility under Voluntary Action Indicated status, which the company said has been adequately addressed.

The inspection concluded successfully with one minor observation that was addressed; the EIR was issued with VAI status. For a pharmaceutical manufacturer whose export business depends critically on regulatory standing in the US and European markets, the clean VAI classification carries significant weight with institutional investors.

The company reiterated its compliance posture unambiguously. Supriya Lifesciences said it remains committed to maintaining full compliance with current Good Manufacturing Practice requirements across all its manufacturing facilities.

Financials: Consistency With Ambition

The fundamental case for Supriya remains anchored in a track record of export-led growth and expanding margins. For Q3 FY26, the company posted consolidated revenues of ₹206.44 crore, an 11.2 percent year-on-year increase, with EBITDA standing at ₹72.08 crore translating to a margin of 34.9 percent, while profit after tax rose to ₹49.68 crore from ₹46.78 crore in Q3 FY25.

Exports continued to be the primary growth engine, contributing approximately 82 percent of total revenues, with Europe remaining the company’s largest market at 36 percent of revenues, followed by Asia at 32 percent.

The full-year FY25 picture was equally compelling. For the year ended March 2025, net profit rose 57.80 percent to ₹187.96 crore and sales grew 22.11 percent to ₹696.49 crore, compared to ₹570.37 crore the prior year.

Commenting on Q3 performance, Satish Wagh, Executive Chairman and Whole Time Director, said the results “reflect consistent execution and steady demand across global markets,” adding that the upcoming commercial launch of the Ambernath formulation facility in Q4 FY26, along with backward integration and new product introductions in regulated markets, positions the company for stronger growth ahead.

(Disclaimer: This article is only for informational purpose. Consult SEBI-registered financial advisor before making any investment decision.)